Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LMNX

Luminex (LMNX) Stock Price, News & Analysis

Luminex logo

About Luminex Stock (NASDAQ:LMNX)

Key Stats

Today's Range
$36.99
$36.99
50-Day Range
$36.66
$37.01
52-Week Range
$20.61
$41.69
Volume
N/A
Average Volume
873,093 shs
Market Capitalization
$1.75 billion
P/E Ratio
72.53
Dividend Yield
1.08%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Receive LMNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Luminex and its competitors with MarketBeat's FREE daily newsletter.

LMNX Stock News Headlines

The Final Frontier
And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.
Luminex Resources Corp (LR)
Luminex (LMNX) Receives FDA Approval for NxTAG RPP
See More Headlines

LMNX Stock Analysis - Frequently Asked Questions

Luminex Co. (NASDAQ:LMNX) announced its earnings results on Sunday, February, 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.12. The company's revenue for the quarter was up 23.1% compared to the same quarter last year.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Luminex investors own include Bristol-Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), Cisco Systems (CSCO), NVIDIA (NVDA), Pfizer (PFE) and QUALCOMM (QCOM).

Company Calendar

Last Earnings
2/07/2021
Today
11/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:LMNX
CUSIP
55027E10
Fax
N/A
Employees
1,325
Year Founded
N/A

Profitability

Net Income
$15.17 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$417.40 million
Cash Flow
$1.12 per share
Book Value
$11.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.75 billion
Optionable
Optionable
Beta
0.56

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:LMNX) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners